Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Asset Writedowns and Impairment: 2022-2024

Historic Asset Writedowns and Impairment for Ptc Therapeutics (PTCT) over the last 3 years, with Dec 2024 value amounting to $159.5 million.

  • Ptc Therapeutics' Asset Writedowns and Impairment fell 69.65% to $400,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $161.2 million, marking a year-over-year change of. This contributed to the annual value of $159.5 million for FY2024, which is 26.75% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Asset Writedowns and Impairment is $159.5 million, which was down 26.75% from $217.8 million recorded in FY2023.
  • Ptc Therapeutics' 5-year Asset Writedowns and Impairment high stood at $217.8 million for FY2023, and its period low was $33.4 million during FY2022.
  • Its 3-year average for Asset Writedowns and Impairment is $136.9 million, with a median of $159.5 million in 2024.
  • In the last 5 years, Ptc Therapeutics' Asset Writedowns and Impairment spiked by 552.41% in 2023 and then decreased by 26.75% in 2024.
  • Ptc Therapeutics' Asset Writedowns and Impairment (Yearly) stood at $33.4 million in 2022, then spiked by 552.41% to $217.8 million in 2023, then dropped by 26.75% to $159.5 million in 2024.